Latest Headlines

Latest Headlines

Quintiles files for $600M IPO

Quintiles made it official on Feb. 15, filing to raise up to $600 million in an IPO after months of rumors and speculation.

UPDATED: Global CRO Quintiles plans to raise up to $600M in IPO

Remember those rumors back in January about a big Quintiles IPO? Somebody had some good information. The global CRO filed its S-1 with the SEC this afternoon, outlining plans to go public in one of the biggest new industry offerings in quite some time.

GoBalto lands major pharma CRO as customer for cloud software

INC Research has signed on to use goBalto's web-based software to boost the process of getting clinical trials up and running, providing the Bay Area startup with what appears to be one of its biggest customer wins yet for the tech.

Piramal continues market access blitz with Abacus takeover

Piramal Healthcare has accelerated its move into market access modeling by snapping up U.K. firm Abacus International for an undisclosed fee. The takeover comes months after India-based Piramal jumped into the sector by snagging Decision Resources Group for $635 million.

Merge wins clinical trials software deal in China

Tigermed Consulting, a CRO based in Shanghai, has opted to use Merge's CTMS for sponsors and CROs to efficiently advance studies.

AstraZeneca turns to Beijing CRO as it scrambles to repair damaged pipeline

After chopping deep into its R&D operations to scale back on expenses, AstraZeneca has struck a pact to outsource part of its drug discovery operations to a CRO in China. Pharmaron, which only recently snipped the ribbon at its new complex in Beijing, will play a supporting role on chemistry, drug metabolism and pharmacokinetics, and efficacy screening for the pharma giant in a multi-year deal announced over the weekend.

Nextrials, CRO partner to lower drug research costs

Nextrials has found a new partner to adopt its clinical trials software, which is tailored for the iPad. InClin, a clinical research organization, plans to use Nextrials' Prism software to speed the start of trials and push down costs of drug development.

India's Advinus inks $36M drug discovery pact with Takeda

India's biotech industry is better known for its contract research operations than novel drug development. But Advinus Pharma, a biotech company supported by the Tata group, is helping to change all that.

Is CRO giant Quintiles planning a multibillion-dollar IPO?

Under its private equity masters at Bain Capital and TPG Capital, Quintiles has been rapidly beefing up its clinical-to-commercial outsourcing operations around the globe. Now Bloomberg reports that the makeover may lead to one very big cash-out as Quintiles execs ponder filing an IPO.

AstraZeneca builds virtual neuroscience drug unit byte by byte

Call it the bionic drug R&D group. Without scads of scientists on hand, AstraZeneca's virtual neuroscience unit relies heavily on information technologies to automate some of the heavy lifting of managing a pipeline of drugs for neurological and psychiatric disorders. In an interview with FierceBiotech IT, AZ research information head John Reynders described the tech platforms supporting the research group.